Skip to main content

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo! Finance
SOUTH SAN FRANCISCO, Calif., August 02, 2021--Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 110,626 restricted stock units of Atara’s common stock to 28 newly hired employees and stock options to purchase an aggregate of 69,744 shares of Atara’s common stock to 8 such newly hired emplo
Continue Reading